Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
Feb 21 (Reuters) - Taisho Pharmaceutical Holdings Co Ltd
4581.T :
* CURI RMB CAPITAL: OPPOSES TAISHO PHARMACEUTICAL HD'S
MANAGEMENT
BUYOUT
Source text: https://www.businesswire.com/news/home/20240220420928/en/Curi-RMB-Capital-Opposes-Taisho-Pharmaceutical-HDs-Management-Buyout
Further company coverage: 4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10